BioRestorative Therapies, Inc. (FRA:9OF)
Germany
· Delayed Price · Currency is EUR 0.8700
+0.0250 (2.96%)
At close: Dec 4, 2025
BioRestorative Therapies Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 0.38 | 0.4 | 0.15 | 0.12 | 0.05 | 0.08 | Upgrade
|
| Revenue Growth (YoY) | 1.70% | 175.03% | 21.70% | 160.44% | -40.26% | -40.77% | Upgrade
|
| Cost of Revenue | 0.03 | 0.03 | - | - | - | - | Upgrade
|
| Gross Profit | 0.36 | 0.37 | 0.15 | 0.12 | 0.05 | 0.08 | Upgrade
|
| Selling, General & Admin | 7.06 | 6.58 | 11.33 | 15.58 | 25.62 | 1.95 | Upgrade
|
| Research & Development | 7.81 | 5.35 | 4.03 | 3.51 | 0.73 | 0.88 | Upgrade
|
| Operating Expenses | 14.87 | 11.93 | 15.37 | 19.09 | 26.35 | 2.83 | Upgrade
|
| Operating Income | -14.51 | -11.56 | -15.22 | -18.97 | -26.31 | -2.75 | Upgrade
|
| Interest Expense | - | - | - | - | -1.82 | -1.64 | Upgrade
|
| Interest & Investment Income | 0.35 | 0.62 | 0.55 | 0.01 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 3.2 | 1.96 | 4.25 | 5.49 | - | -2.14 | Upgrade
|
| EBT Excluding Unusual Items | -10.96 | -8.98 | -10.42 | -13.47 | -28.12 | -6.53 | Upgrade
|
| Other Unusual Items | -1.71 | - | - | 0.25 | -16.18 | -4.74 | Upgrade
|
| Pretax Income | -12.67 | -8.98 | -10.42 | -13.22 | -44.3 | -11.27 | Upgrade
|
| Net Income | -12.67 | -8.98 | -10.42 | -13.22 | -44.3 | -11.27 | Upgrade
|
| Net Income to Common | -12.67 | -8.98 | -10.42 | -13.22 | -44.3 | -11.27 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 8 | 4 | 4 | 1 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 8 | 4 | 4 | 1 | 0 | Upgrade
|
| Shares Change (YoY) | 24.38% | 84.05% | 16.60% | 204.60% | 200.92% | - | Upgrade
|
| EPS (Basic) | -1.48 | -1.16 | -2.47 | -3.65 | -37.30 | -28.56 | Upgrade
|
| EPS (Diluted) | -1.48 | -1.16 | -2.47 | -3.65 | -37.30 | -28.56 | Upgrade
|
| Free Cash Flow | -10.77 | -8.34 | -6.6 | -6.18 | -3.36 | -1.96 | Upgrade
|
| Free Cash Flow Per Share | -1.25 | -1.07 | -1.56 | -1.71 | -2.83 | -4.98 | Upgrade
|
| Gross Margin | 93.34% | 93.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -3785.07% | -2881.60% | -10439.49% | -15838.08% | -57191.03% | -3574.13% | Upgrade
|
| Profit Margin | -3304.77% | -2239.25% | -7145.20% | -11036.98% | -96311.51% | -14639.85% | Upgrade
|
| Free Cash Flow Margin | -2809.20% | -2078.94% | -4527.61% | -5157.20% | -7305.58% | -2550.99% | Upgrade
|
| EBITDA | -14.3 | -11.37 | -15.06 | -18.85 | -26.22 | -2.63 | Upgrade
|
| D&A For EBITDA | 0.21 | 0.19 | 0.17 | 0.12 | 0.09 | 0.12 | Upgrade
|
| EBIT | -14.51 | -11.56 | -15.22 | -18.97 | -26.31 | -2.75 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.